In the CVD‐REAL study, which was a multi‐national study based on electronic records and claims databases, SGLT2 inhibitor use was associated with a significant reduction in the risk of mortality and heart failure, regardless of pre‐existing cardiovascular disease.15 Here, SLC5A2 is linked to cardiovascular disorder.